Incyte Eyes Big Phase III IDO Expansion, NewLink Plans First Pivotal Trial
NewLink is hoping FDA will accept its plans to run one Phase III registrational study of its IDO pathway inhibitor indoximod with an anti-PD-1 agent in frontline melanoma; Incyte updates its Phase III plans for epacadostat.
You may also be interested in...
NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO
There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.
A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug
Following termination of pivotal trials in three tumor types testing its in-house IDO inhibitor BMS-986205, Bristol says it is "working quickly" to assess the development of Opdivo with Incyte's epacadostat.
NewLink Absorbs Big Blow As Roche Exits IDO Inhibitor Partnership
Genentech's statements about IDO as an immuno-oncology target raise questions about the future of the drug class, but IDO leader Incyte has emerged unscathed for now.